Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: Clinical experience at a single center

Bone Marrow Transplantation

Volumn 48, Issue 7, 2013, Pages 1010-1012

  Solano, C ^a,b   Munoz Cobo B ^a   Gimenez E ^a   Remigia, M J ^a   Amat, P ^a   Clari, M A ^a   Bravo, D ^a   Benet, I ^a   Montoro, J ^a   Navarro, D ^a,b  

^a Instituto Universitario IVI INCLIVA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIGEN PP65; VIRUS DNA;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGENEMIA ASSAY; ANTIVIRAL THERAPY; ASSAY; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INFECTION PREVENTION; LETTER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT MONITORING; PRE EMPTIVE VIRAL THERAPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 84880206603     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.286     Document Type: Letter

References (10)

1. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711-5719.
2. Lilleri D, Gerna G, Furione M, Bernardo ME, Giorgiani G, Telli S et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood 2007; 110: 2757-2760.
3. Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L, Alessandrino EP. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008; 41: 873-839.
4. Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, Mori S et al. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone Marrow Transplant 2010; 45: 1325-1332.
5. Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1687-1699.
6. Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008; 46: 3311-3318.
7. Ljungman P, Griffiths P, Paya C. Definitions of HCMV infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
8. Tormo N, Solano C, Benet I, Clari MA, Nieto J, de la Cámara R et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2010; 45: 543-549.
9. Clari MA, Bravo D, Costa E, Muñ oz-Cobo B, Solano C, Remigia MJ et al. Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn Microbiol Infect Dis 2012, doi:pii: S0732-8893: 00434-00438.
10. Fryer JF, Heath AB, Anderson R, Minor PD. The collaborative study group. Collaborative study to evaluate the proposed 1st WHO International Standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2010, WHO/BS/10.2138.